All In Biotech

NDA 215429 · Almatica

Venlafaxine Besylate

Venlafaxine Besylate · Oral

Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jun 29, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

231

58 Phase 3, 14 recruiting

FAERS reports

58,351

48,491 serious, 8,442 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )]. Venlafaxine Extended-Release Tablets are not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Venlafaxine Extended-Release Tablets are not approved for use in pediatric patients ( 8.4 )

What it is approved for

From the label in effect Oct 9, 2025.

Venlafaxine Extended-Release Tablets are indicated in adults for the treatment of: Major depressive disorder (MDD) Generalized Anxiety Disorder (GAD) Venlafaxine Extended-Release Tablets are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated in adults for the treatment of: Major Depressive Disorder (MDD) ( 1 ) Generalized Anxiety Disorder (GAD) ( 1 )

Mechanism: The mechanism of action of venlafaxine in treatment of MDD and GAD is unclear, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake of serotonin and norepinephrine.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VENLAFAXINE BESYLATE · VENLAFAXINE BESYLATE EQ 112.5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Venlafaxine" as an intervention, any sponsor and status, largest first.

All 231 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,903
  • toxicity to various agents3,736
  • fatigue3,326
  • nausea3,255
  • off label use2,815
  • completed suicide2,791
  • drug interaction2,670
  • headache2,617
  • dizziness2,416
  • diarrhoea2,171
  • depression2,082
  • anxiety2,044

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200477
200576
200613
20073
200831
2009236
2010656
2011985
20121,428
20131,551
20141,842
20152,808
20163,305
20173,771
20184,883
20195,378
20205,208
20214,467
20224,129
20234,709
20244,784
20254,549
20263,461

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,067 on PubMed

Sponsor: Almatica

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.